Product Description
Mechanisms of Action: M1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | Canada | Chile | Egypt | Hong Kong | India | Ireland | Israel | Italy | Korea | Latvia | Malaysia | Malta | Mexico | New Zealand | Peru | Philippines | Portugal | Russia | Singapore | Spain | Sri Lanka | Taiwan | Thailand | Ukraine | United Kingdom | United States | Venezuela
Approved Indications: Spasm | Anticholinergic Syndrome | Irritable Bowel Syndrome
Known Adverse Events: Dizziness | Asthenia
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|